Emergent Unveils Enhancement Plan for Baltimore Facility Following FDA Report
09:58 AM EDT, 05/12/2021 (MT Newswires) -- Emergent Biosolutions (EBS) on Wednesday unveiled a comprehensive quality enhancement plan for its Baltimore Bayview facility in response to the US Food and Drug Administration's observations of unsanitary practices at the plant, which manufactures COVID-19 vaccine for Johnson & Johnson (JNJ).
In a filing with the US Securities and Exchange Commission, the company said it has already started making improvements and it is working with both the FDA and Johnson and & Johnson to resume vaccine production at the facility. The plant is where up to 15 million doses of the Johnson & Johnson vaccine were ruined and FDA regulators later found that additional doses may have been contaminated.
Shares were 1.1% higher in morning session.
Price: 59.42, Change: +0.62, Percent Change: +1.05